Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies Closes Ion Torrent Acquisition

Premium

Life Technologies said this week that is has completed its acquisition of Ion Torrent for $375 million in cash and stock, a deal first announced in August (IS 8/24/2010).

Contingent on the achievement of milestones, Life Tech may pay up to $350 million in additional considerations for the company.

Life Tech reiterated that it plans to launch the first product using the Ion Torrent technology — the Personal Genome Machine sequencer — before the end of the year.

It said the Ion Torrent sequencing system "is simpler, faster, less expensive, and more scalable than other sequencing technologies."

Ion Torrent first publicly presented its technology at a conference earlier this year (IS 3/2/2010). It sequences DNA by electronically measuring hydrogen ions that are released when a polymerase incorporates a nucleotide.

Last month, Life Tech CEO Greg Lucier said that the technology could also be used to analyze different types of single molecules, including DNA (IS 9/28/2010).

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.